Why the study?
Does prophylactic ICD therapy improve survival in high-risk patients with coronary heart disease and ischemic cardiomyopathy?
Does prophylactic ICD therapy improve survival in high-risk patients with coronary heart disease and ischemic cardiomyopathy?
Prophylactic ICD therapy is indicated to improve survival in patients with coronary heart disease and advanced left ventricular dysfunction who meet MADIT eligibility criteria.
May support prophylactic ICD use in MADIT-eligible ischemic cardiomyopathy; leaves open refinement of selection criteria with contemporary therapies.
The MADIT-I study was a proof-of-principle study, and this randomized trial showed that the implantable cardioverter defibrillator (ICD) saves lives in high-risk patients with coronary heart disease. The MADIT-II study showed that prophylactic ICD therapy was associated with significantly improved survival in patients with ischemic cardiomyopathy, as defined by documented coronary heart disease and advanced left ventricular dysfunction, without requiring screening for ventricular arrhythmias or inducibility by electrophysiologic testing. Taken together, these two trials, as well as the results from several other randomized ICD trials, indicate that ICD therapy is indicated in coronary patients who meet MADIT-I or MADIT-II eligibility criteria and are not excluded by major noncardiac comorbidity.
No takes yet. Share an insight, caveat, or question.
Arthur J. Moss (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: